Light chains are small proteins that form part of every antibody your immune system makes. In multiple myeloma, cancerous plasma cells produce enormous quantities of a single type of light chain, and measuring these proteins in your blood is one of the primary ways doctors diagnose the disease and track how well treatment is working.
How Light Chains Work in a Healthy Immune System
Every antibody your body produces is built from two types of protein chains: two heavy chains and two light chains. The heavy chains weigh about 50 kilodaltons each, while the light chains are roughly half that size at 25 kilodaltons. Together, they form the Y-shaped molecule that locks onto bacteria, viruses, and other threats.
There are two varieties of light chain, called kappa and lambda. A single antibody always carries one type or the other, never a mix of both. Despite their different names, kappa and lambda light chains do the same job. The tip of each light chain pairs with the tip of a heavy chain to form the antibody’s binding site, the part that recognizes and attaches to a specific invader. Each antibody has two of these binding sites, one at the end of each arm of the Y.
Normal plasma cells naturally produce slightly more light chains than heavy chains. The extras that don’t get paired into complete antibodies circulate in your blood as “free” light chains. In a healthy person, serum kappa levels typically fall between 3.3 and 19.4 mg/L, lambda levels between 5.7 and 26.3 mg/L, and the ratio of kappa to lambda sits between 0.26 and 1.65.
What Goes Wrong in Multiple Myeloma
Multiple myeloma is a cancer of plasma cells. A single plasma cell turns malignant and begins cloning itself, and all of those copies churn out the same identical antibody protein. Because every plasma cell already tends to make more light chains than heavy chains, the cancerous clones flood the bloodstream with massive amounts of one specific free light chain, either kappa or lambda.
About 15% of myeloma patients have a subtype called light chain myeloma, where the cancerous cells have lost the ability to produce heavy chains altogether. These cells secrete only free light chains, with no complete antibody attached. The remaining patients typically produce whole antibodies (most commonly IgG, followed by IgA), but they still overproduce free light chains alongside them. In either case, the surplus light chains are a defining feature of the disease.
How Excess Light Chains Damage the Kidneys
One of the most serious consequences of light chain overproduction is kidney injury. When the kidneys filter blood, free light chains pass into the tubules, the tiny tubes where urine is formed. In high concentrations, these light chains bind to a protein naturally present in the kidney’s filtering loops, forming solid plugs called light chain casts. The casts physically block the tubules, and the resulting pressure can rupture them.
The damage doesn’t stop with obstruction. The light chains also trigger chemical reactions that produce hydrogen peroxide and activate inflammatory signaling pathways inside kidney cells. This leads to cell death, chronic inflammation, and scarring of the tissue surrounding the tubules. The combined effect of blockage, inflammation, and scarring is called cast nephropathy, and it is a major cause of kidney failure in myeloma patients.
Testing for Light Chains
Doctors use a blood test called the serum free light chain (sFLC) assay to measure kappa and lambda levels independently. The test can detect free light chains at concentrations below 1.0 mg/L, making it far more sensitive than older methods that relied on urine samples. The most important number from this test is the ratio between the involved light chain (whichever one is abnormally high) and the uninvolved one. A ratio that’s significantly skewed away from the normal 0.26 to 1.65 range signals that a single clone of plasma cells is dominating production.
Urine testing for light chains still plays a role. When free light chains spill into urine, they’re historically called Bence Jones proteins, named after the physician who first described them in the 1840s. Urine immunofixation remains particularly useful for detecting a related condition called amyloidosis, where misfolded light chains deposit in organs. But for diagnosing myeloma itself, combining a standard blood protein electrophoresis with the serum free light chain assay identifies essentially 100% of cases.
Light Chains as a Diagnostic Marker
The International Myeloma Working Group includes the free light chain ratio in its official diagnostic criteria. A ratio of 100 or greater between the involved and uninvolved light chain, with the involved chain measuring at least 100 mg/L, qualifies as a myeloma-defining biomarker on its own. That means even without other classic signs like bone lesions, a dramatically skewed light chain ratio can be enough to confirm a diagnosis when other criteria are also met.
Light chain myeloma can be trickier to catch than the more common subtypes because these patients don’t produce the complete antibody “spike” that shows up easily on standard blood protein tests. Their disease is only visible through the free light chain assay or urine testing, which is one reason these sensitive tests have become standard in the diagnostic workup.
Tracking Treatment Response
Once treatment begins, the serum free light chain level becomes one of the key numbers doctors follow. Because the test is so sensitive, it can detect small amounts of remaining disease that urine tests miss entirely. A large UK study found that only 11% of light chain myeloma patients achieved a true complete response when measured by the serum test, compared to 32% when measured by the less sensitive urine method. In other words, urine testing was giving an overly optimistic picture of how well treatment was working in a substantial number of patients.
Multiple studies across international myeloma research groups have confirmed that patients whose light chain levels and ratio return to normal after treatment have significantly better long-term outcomes. Conversely, patients whose involved light chain stays elevated or whose ratio remains abnormal after induction therapy face a higher risk of the disease progressing sooner. This makes the serum free light chain assay not just a snapshot of current disease activity but a meaningful predictor of what’s ahead.
For patients, this translates to a simple routine: regular blood draws that track a specific number over time. A falling involved light chain level and a ratio moving back toward normal are concrete signs that treatment is doing its job. A rising level or widening ratio is often one of the earliest signals of relapse, sometimes appearing before symptoms do.